# Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma

> **NCT07637526** · — · NOT_YET_RECRUITING · sponsor: **PETHEMA Foundation** · enrollment: 100 (estimated)

## Conditions studied

- Relapse Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin
- **DRUG:** Bortezomib
- **DRUG:** Dexamethasone
- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT07637526
- **Lead sponsor:** PETHEMA Foundation
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2027-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-06-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07637526

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07637526, "Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07637526. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*